Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
$24.18
-$4.21(-8.86%)
At close: 4:00 PM EST
$24.18
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$23.04 - $48.92
Previous CloseN/A
Volume7.58M
Average Volume (3M)11.11M
Market Cap
$9.67B
Enterprise Value$6.30B
Total Cash (Recent Filing)$4.50B
Total Debt (Recent Filing)$734.00M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Feb 19, 2026EPS Estimate
-2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding390,679,500
10 Day Avg. Volume10,498,503
30 Day Avg. Volume11,114,719
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.46
Price to Sales (P/S)4.99
P/FCF Ratio-3.94
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit23.78
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$39.56Price Target Upside63.61% Upside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company is implementing cost-cutting initiatives, which are coming in more efficiently than estimates, contributing to financial stability.
Financial PositionThe cash and investments guide is raised to $6.5B-$7.0B, suggesting a stronger financial position.
Oncology PipelineThe prioritization of the company’s oncology assets is seen as having significant value, with potential Phase III adjuvant melanoma data potentiating quicker approval.
Bears Say
CMV Program DiscontinuationThe Phase 3 pivotal study of mRNA-1647 (CMV vaccine) did not meet its primary efficacy endpoint, leading to the discontinuation of congenital CMV development.
Profitability PathThe path to profitability is still seen as challenging, with updated models reflecting lower future expectations for COVID and RSV.
Revenue ChallengesThe company's COVID-19 vaccine sales estimate has been lowered, reflecting difficulties in maintaining revenue levels.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $23.04 and its highest was $48.92 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $9.67B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Feb 19, 2026 which is in 90 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 06, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$1.875 by $1.365.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.64.
How many shares outstanding does Moderna have?
Moderna has 390,679,500 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$0.51 in its last earnings report, beating expectations of -$1.875. Following the earnings report the stock price went up 3.268%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.56 (63.61% Upside)
$39.56 (63.61% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 73%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 422.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.15%
12-Months-Change
Fundamentals
Return on Equity
-29.32%
Trailing 12-Months
Asset Growth
-23.21%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reduction, strategic partnerships, and product approvals. However, these positives were tempered by notable challenges, including a significant revenue decline, a net loss for the quarter, and the discontinuation of the CMV vaccine program.View all MRNA earnings summariesMRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
MRNA Stock 12 Month Forecast
Average Price Target
$39.56
▲(63.61% Upside)
Technical Analysis
Ownership Overview
7.71% Insiders
19.57% Mutual Funds
9.11% Other Institutional Investors
39.24% Public Companies and Individual Investors